Premenstrual Syndrome Treatment Market Size, Growth, Trends, Forecast (2025-2033)

Rohit Joshi avatar   
Rohit Joshi
These innovations are likely to grow product pipelines, boost effectiveness, and lessen side effects, creating strong potential for future market growth.

The Premenstrual Syndrome Treatment Market is set to show a growth rate of about 4.74% during the forecast period (2025-2033F).

Premenstrual syndrome (PMS) is a health issue that involves physical and psychological symptoms occurring about five days before menstruation and ending a few days after it begins. The most common symptoms are appetite changes, breast tenderness, abdominal pain, back pain, headache, fatigue, insomnia, depressive affect, irritability, angry outbursts, and anxiety. Some women encounter mild discomfort, whereas others experience major disruptions in their daily routines. The condition is related to hormonal changes, serotonin levels, and lifestyle changes such as stress and diet.

The PMS treatment market is growing steadily due to rising investments in research and development (R&D) focused on creating more effective and safer therapies. Traditional PMS therapies have mainly relied on analgesics, antidepressants, and oral contraceptives, but these treatments often target only specific symptoms. To address this issue, pharmaceutical and biotech companies are developing targeted hormonal and non-hormonal therapies that attack the underlying causes of PMS and PMDD. Furthermore, advances in hormonal regulation and controlled-release drug delivery systems are enhancing treatment results and helping patients stick with their therapies. Collaborations between pharmaceutical companies and women’s health startups are also speeding up clinical progress. The increased R&D focus on PMS shows a wider recognition of women’s health as an underfunded treatment area. These innovations are likely to grow product pipelines, boost effectiveness, and lessen side effects, creating strong potential for future market growth.

List of Top Companies Operating in Premenstrual Syndrome Treatment Worldwide:

The global Premenstrual Syndrome Treatment market has several major players, including Midol (Bayer), Motrin (Kenvue), Teva Pharmaceuticals USA, Inc., Herbalife International of America, Inc., and Amway Singapore Pte.Ltd. More information about these companies has been provided below:

1.     Midol (Bayer)

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, pain and cardiovascular risk prevention products, digestive health products, allergy products, and cold and cough products. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

2.     Motrin (Kenvue)

Kenvue Inc. operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold, and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. The Essential Health segment offers oral and baby, women’s health, wound, and other care products under the Listerine, Johnson’s, Band-Aid, Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.

Access sample report (including graphs, charts, and figures) - https://univdatos.com/reports/premenstrual-syndrome-treatment-market?popup=report-enquiry

3.     Teva Pharmaceuticals USA, Inc.

Teva Pharmaceuticals USA, Inc. manufactures and markets generic drugs in the United States. It offers generic products for various therapeutic options, such as cardiovascular, anti-infective, central nervous system, anti-inflammatory, oncolytic, anti-diabetic, analgesic, dermatologic, respiratory, and women’s health. The company offers its products in various dosage forms, such as tablets, capsules, injectables, creams, ointments, inhalants, solutions, and suspensions. It serves patients through distributors. Teva Pharmaceuticals USA, Inc. was formerly known as Lemmon Pharmacal Company and changed its name to Teva Pharmaceuticals USA, Inc. in 1996. The company was founded in 1901 and is based in Parsippany, New Jersey, with facilities throughout the United States. Teva Pharmaceuticals USA, Inc. operates as a subsidiary of Teva Pharmaceutical Industries Limited.

4.     Herbalife International of America, Inc.

Herbalife International of America, Inc. manufactures and sells nutrition, weight-management, energy, and fitness products. The company offers specialized nutrition products for heart health, men's and women's health, digestion and immune health, stress management, and children's health products; energy and hydration products; and personal care products, such as skin, bath, and body care products. It sells its products through and catalog retailing and a network of independent distributors worldwide. The company was founded in 1980 and is based in Los Angeles, California, with additional locations in America, the Middle East and Africa, Europe, and the Asia Pacific. Herbalife International of America, Inc. operates as a subsidiary of Herbalife Ltd.

5.     Amway Singapore Pte.Ltd.

Amway Singapore Pte Ltd, incorporated in 1979, is a private company limited by shares registered in Singapore. The company specializes in wholesale trade of a variety of goods without a dominant product. It is a subsidiary of Amway Corporation, one of the world's largest direct selling companies. Amway Singapore is a proud member of the Direct Selling Association of Singapore (DSAS), the Health Supplements Industry Association of Singapore, and is CaseTrust-accredited, upholding the highest standards of business ethics and customer satisfaction.

Contact Us:

UnivDatos

Email - contact@univdatos.com

Website - www.univdatos.com

 

Geen reacties gevonden